share_log

HC Wainwright & Co. Maintains Buy on ProQR Therapeutics, Raises Price Target to $5

Benzinga ·  Mar 30, 2023 06:28

HC Wainwright & Co. analyst Andrew Fein maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and raises the price target from $1.5 to $5.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment